Sandoz
As of the edition of 20 October 2026, Sandoz runs 43 drugs, 37 of them marketed; it is on route A at 1 target and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Sandoz was acquired in 2023.
The records place 2 company names in this family.
- Sandoz: acquired in 2023
Drugs by status
| Status | Count |
|---|---|
| Marketed | 37 |
| Went quiet | 3 |
| Stopped | 1 |
| Status not established | 2 |
| Total | 43 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Cyclophosphamide anhydrous | none listed | 0 |
| Docetaxel anhydrous | none listed | 0 |
| Pemetrexed | none listed | 7 |
| Prednisolone | none listed | 6 |
| Topotecan | none listed | 1 |
| Methylphenidate | none listed | 11 |
| Somatropin | Ended 2003 (orphan exclusivity) | 4 |
| Zoledronic acid anhydrous | none listed | 4 |
| Ondansetron | none listed | 0 |
| Estradiol | Ends 2032 (patent) | 6 |
| Ciprofloxacin | none listed | 0 |
| Isoniazid | none listed | 0 |
| Methadone | none listed | 2 |
| Timolol | none listed | 5 |
| Brimonidine | none listed | 9 |
| Cabazitaxel | Ended 2025 (patent) | 0 |
| Travoprost | none listed | 2 |
| Rivastigmine | none listed | 4 |
| Bivalirudin | none listed | 0 |
| Micafungin | none listed | 0 |
| Brinzolamide | none listed | 3 |
| Fluvastatin | none listed | 1 |
| Pilocarpine | none listed | 2 |
| Prednisolone acetate | none listed | 2 |
| Nelarabine | none listed | 0 |
A route B row is one company at one target. 12 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 1 target, route B at 1 target.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Sandoz needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Immune system: 10 trials led
- Infections: 10 trials led
- Urinary and reproductive: 10 trials led